113 related articles for article (PubMed ID: 12734658)
1. Analysis of TP53 and PTEN in gliomatosis cerebri.
Mawrin C; Kirches E; Schneider-Stock R; Scherlach C; Vorwerk C; Von Deimling A; Van Landeghem F; Meyermann R; Bornemann A; Müller A; Romeike B; Stoltenburg-Didinger G; Wickboldt J; Pilz P; Dietzmann K
Acta Neuropathol; 2003 Jun; 105(6):529-36. PubMed ID: 12734658
[TBL] [Abstract][Full Text] [Related]
2. Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide.
Mawrin C; Aumann V; Kirches E; Schneider-Stock R; Scherlach C; Vogel S; Mittler U; Dietzmann K; Krause G; Weis S
J Neurooncol; 2001 Oct; 55(1):11-7. PubMed ID: 11804278
[TBL] [Abstract][Full Text] [Related]
3. Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis.
Kros JM; Zheng P; Dinjens WN; Alers JC
J Neuropathol Exp Neurol; 2002 Sep; 61(9):806-14. PubMed ID: 12230327
[TBL] [Abstract][Full Text] [Related]
4. Gliomatosis cerebri: molecular pathology and clinical course.
Herrlinger U; Felsberg J; Küker W; Bornemann A; Plasswilm L; Knobbe CB; Strik H; Wick W; Meyermann R; Dichgans J; Bamberg M; Reifenberger G; Weller M
Ann Neurol; 2002 Oct; 52(4):390-9. PubMed ID: 12325066
[TBL] [Abstract][Full Text] [Related]
5. Distribution of p53 alterations in a case of gliomatosis cerebri.
Mawrin C; Lins H; Kirches E; Schildhaus HU; Scherlach C; Kanakis D; Dietzmann K
Hum Pathol; 2003 Jan; 34(1):102-6. PubMed ID: 12605375
[TBL] [Abstract][Full Text] [Related]
6. Alterations of cell cycle regulators in gliomatosis cerebri.
Mawrin C; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Mawrin A; Kirches E; Schneider-Stock R; Boltze C; Vorwerk CK; von Deimling A; Stoltenburg-Didinge G; Bornemann A; Romeike B; Sellhaus B; Dietzmann K
J Neurooncol; 2005 Apr; 72(2):115-22. PubMed ID: 15925990
[TBL] [Abstract][Full Text] [Related]
7. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C
Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of molecular alterations in microdissected archival gliomas.
Walker C; Joyce KA; Thompson-Hehir J; Davies MP; Gibbs FE; Halliwell N; Lloyd BH; Machell Y; Roebuck MM; Salisbury J; Sibson DR; Du Plessis D; Broome J; Rossi ML
Acta Neuropathol; 2001 Apr; 101(4):321-33. PubMed ID: 11355303
[TBL] [Abstract][Full Text] [Related]
9. Independent molecular development of metachronous glioblastomas with extended intervening recurrence-free interval.
Martinez R; Schackert HK; von Kannen S; Lichter P; Joos S; Schackert G
Brain Pathol; 2003 Oct; 13(4):598-607. PubMed ID: 14655763
[TBL] [Abstract][Full Text] [Related]
10. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas.
Cheng Y; Pang JC; Ng HK; Ding M; Zhang SF; Zheng J; Liu DG; Poon WS
Histopathology; 2000 Nov; 37(5):437-44. PubMed ID: 11119125
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic alterations in gliomatosis cerebri: what can we learn about the origin and course of the disease?
Mawrin C
Acta Neuropathol; 2005 Dec; 110(6):527-36. PubMed ID: 16222524
[TBL] [Abstract][Full Text] [Related]
12. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.
Koenig A; Bianco SR; Fosmire S; Wojcieszyn J; Modiano JF
Vet Pathol; 2002 Jul; 39(4):458-72. PubMed ID: 12126149
[TBL] [Abstract][Full Text] [Related]
13. Assessment of tumor cell invasion factors in gliomatosis cerebri.
Mawrin C; Schneider T; Firsching R; Wiedemann FR; Dietzmann K; Bornemann A; Romeike BF; Sellhaus B; von Deimling A
J Neurooncol; 2005 Jun; 73(2):109-15. PubMed ID: 15981099
[TBL] [Abstract][Full Text] [Related]
14. Genetic interactions between Pten and p53 in radiation-induced lymphoma development.
Mao JH; Wu D; Perez-Losada J; Nagase H; DelRosario R; Balmain A
Oncogene; 2003 Nov; 22(52):8379-85. PubMed ID: 14627978
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors.
Mawrin C; Kirches E; Boltze C; Dietzmann K; Roessner A; Schneider-Stock R
Virchows Arch; 2002 Jun; 440(6):610-5. PubMed ID: 12070601
[TBL] [Abstract][Full Text] [Related]
16. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
17. PTEN mutations in malignant gliomas and their relation with meningeal gliomatosis.
Izumoto S; Ohnishi T; Kanemura H; Arita N; Maruno M; Moriuchi T; Suzuki S; Yoshimine T
J Neurooncol; 2001 May; 53(1):21-6. PubMed ID: 11678426
[TBL] [Abstract][Full Text] [Related]
18. Presence of allelic loss and PTEN mutations in malignant gliomas from Malay patients.
Zainuddin N; Jaafar H; Isa MN; Abdullah JM
Med J Malaysia; 2004 Oct; 59(4):468-79. PubMed ID: 15779579
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of molecular genetic alterations associated with tumor progression in a case of gliomatosis cerebri.
Braeuninger S; Schneider-Stock R; Kirches E; Powers JM; Korones DN; Mawrin C
J Neurooncol; 2007 Mar; 82(1):23-7. PubMed ID: 16955219
[TBL] [Abstract][Full Text] [Related]
20. Functional evaluation of p53 and PTEN gene mutations in gliomas.
Kato H; Kato S; Kumabe T; Sonoda Y; Yoshimoto T; Kato S; Han SY; Suzuki T; Shibata H; Kanamaru R; Ishioka C
Clin Cancer Res; 2000 Oct; 6(10):3937-43. PubMed ID: 11051241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
